Neurocrine Launches $53/Share Tender Offer for Soleno Therapeutics (SLNO)

The Offer

Neurocrine Biosciences (NBIX), through its wholly owned subsidiary Sigma Merger Sub, is launching a cash tender offer for all outstanding shares of Soleno Therapeutics (SLNO) at $53.00 per share. The deal, announced April 6, 2026, values Soleno at approximately $2.9 billion. Soleno is a rare disease pharmaceutical company whose lead product, VYKAT XR (diazoxide choline), treats hyperphagia in Prader-Willi syndrome.

The offer represents a 34% premium to Soleno's unaffected closing price of approximately $39.55 on April 2, 2026, and a 51% premium to the 30-day volume-weighted average price. Soleno's board unanimously approved the deal and recommends that stockholders tender their shares. The tender offer has not yet formally commenced — the filings to date are pre-commencement communications — but Neurocrine is required to launch the offer within ten business days of the April 5 merger agreement, putting the expected commencement around April 21, 2026.

Why This Is Interesting

The market has already priced this deal as nearly done. SLNO trades at $52.35, leaving a spread of just $0.65 per share, or about 1.2%. That tight spread tells you the market sees minimal risk of this falling apart, and for good reason: the deal is fully funded with cash on hand and a modest amount of pre-payable debt, carries no financing contingency, and Neurocrine is a large-cap biopharma with the resources to close.

For tender offer investors looking for a quick, low-risk flip, this one is borderline. A 1.2% return over roughly six weeks (from now through expected close in early-to-mid June) isn't bad on an annualized basis, but the margin of safety is razor-thin. There's no disclosed odd-lot provision in the pre-commencement filings, so small investors don't have a guaranteed-fill advantage here. If you're already holding SLNO from before the announcement, the path is clear: wait for the tender offer to commence and tender your shares. If you're looking to get in now, the reward barely justifies the transaction costs and capital commitment unless you're putting meaningful size to work.

Key Terms

• Consideration: $53.00 per share, all cash, no interest
• Minimum tender condition: Shares tendered must represent more than 50% of outstanding shares (majority condition)
• Financing: Cash on hand plus modest pre-payable debt. No financing contingency — the money is committed
• Regulatory approvals: HSR Act clearance required. No CFIUS or foreign regulatory approvals mentioned
• Back-end merger: Following the tender offer, Purchaser will merge with Soleno under Section 251(h) of Delaware law — no stockholder vote required. All remaining shares convert to $53.00 in cash
• No-shop provision: Soleno cannot solicit competing offers, but the board can respond to unsolicited superior proposals subject to Neurocrine's match right
• Termination fees: Soleno owes $95.25 million if it terminates to accept a superior proposal. Neurocrine owes $141.5 million if the deal fails due to antitrust issues
• Support agreements: Soleno's CEO (Anish Bhatnagar) and former CFO (James Mackaness) have agreed to tender their shares, representing approximately 1.01% of outstanding stock
• Top-up option / short-form merger: The Section 251(h) merger eliminates the need for a top-up — if the tender offer succeeds, the merger closes automatically

Timeline

Risks

• HSR / antitrust clearance: This is the primary gating condition. Neurocrine is expanding into rare metabolic diseases, which is distinct from its existing neuroscience focus, so antitrust risk appears low. The $141.5 million reverse termination fee Neurocrine would owe if antitrust blocks the deal signals confidence but also acknowledges the regulatory checkpoint.
• Minimum tender condition: More than 50% of outstanding shares must be tendered. With unanimous board support, a clear premium, and the two insider support agreements, failure to reach the threshold is unlikely but not impossible.
• Competing offer risk: While the no-shop provision limits Soleno's ability to solicit alternatives, the board retains fiduciary outs for genuinely superior proposals. Given SLNO's 52-week high of $88.49 versus the $53.00 offer, some shareholders may view the price as opportunistic — Soleno was trading much higher a year ago. A third-party bid is unlikely but worth monitoring.
• Material adverse change: Standard MAC clause allows Neurocrine to walk away if Soleno suffers a material adverse effect, with typical carve-outs for industry-wide and macroeconomic conditions.
• Tight spread leaves no cushion: At $52.35, you're paying within 1.2% of the offer price. If any complication arises — a delayed HSR review, a litigation challenge, or an adverse development with VYKAT XR — the stock could gap down meaningfully while you're waiting for the offer to close.

This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing on EDGAR and consult your own advisors before making any decisions.